<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>13</volume><submitter>Needhamsen M</submitter><funding>European Research Council</funding><pubmed_abstract>Multiple Sclerosis (MS) is an autoimmune, neurological disease, commonly presenting with a relapsing-remitting form, that later converts to a secondary progressive stage, referred to as RRMS and SPMS, respectively. Early treatment slows disease progression, hence, accurate and early diagnosis is crucial. Recent advances in large-scale data processing and analysis have progressed molecular biomarker development. Here, we focus on small RNA data derived from cell-free cerebrospinal fluid (CSF), cerebrospinal fluid cells, plasma and peripheral blood mononuclear cells as well as CSF cell methylome data, from people with RRMS (n = 20), clinically/radiologically isolated syndrome (CIS/RIS, n = 2) and neurological disease controls (n = 14). We applied multiple co-inertia analysis (MCIA), an unsup</pubmed_abstract><journal>Frontiers in genetics</journal><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9713411</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Integration of small RNAs from plasma and cerebrospinal fluid for classification of multiple sclerosis</pubmed_title><pmcid>PMC9713411</pmcid><funding_grant_id>818170</funding_grant_id><pubmed_authors>Needhamsen M</pubmed_authors><pubmed_authors>Piket E</pubmed_authors><pubmed_authors>Jagodic M</pubmed_authors><pubmed_authors>Zheleznyakova G</pubmed_authors><pubmed_authors>Hagemann-Jensen M</pubmed_authors><pubmed_authors>Gierlich J</pubmed_authors><pubmed_authors>Han Y</pubmed_authors><pubmed_authors>Ekman D</pubmed_authors><pubmed_authors>Khoonsari P</pubmed_authors></additional><is_claimable>false</is_claimable><name>Integration of small RNAs from plasma and cerebrospinal fluid for classification of multiple sclerosis</name><description>Multiple Sclerosis (MS) is an autoimmune, neurological disease, commonly presenting with a relapsing-remitting form, that later converts to a secondary progressive stage, referred to as RRMS and SPMS, respectively. Early treatment slows disease progression, hence, accurate and early diagnosis is crucial. Recent advances in large-scale data processing and analysis have progressed molecular biomarker development. Here, we focus on small RNA data derived from cell-free cerebrospinal fluid (CSF), cerebrospinal fluid cells, plasma and peripheral blood mononuclear cells as well as CSF cell methylome data, from people with RRMS (n = 20), clinically/radiologically isolated syndrome (CIS/RIS, n = 2) and neurological disease controls (n = 14). We applied multiple co-inertia analysis (MCIA), an unsup</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Jan</publication><modification>2025-04-04T07:47:59.146Z</modification><creation>2025-02-19T04:13:56.972Z</creation></dates><accession>S-EPMC9713411</accession><cross_references/></HashMap>